Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 161 articles:
HTML format



Single Articles


    January 2025
  1. GOLANI R, Kagenaar E, Jegu J, Belot A, et al
    Socio-economic inequalities in second primary cancer incidence: A competing risks analysis of women with breast cancer in England between 2000 and 2018.
    Int J Cancer. 2025 Jan 24. doi: 10.1002/ijc.35320.
    PubMed     Abstract available


  2. ZAHWE M, Bendahhou K, Eser S, Mukherji D, et al
    Current and future burden of female breast cancer in the Middle East and North Africa region using estimates from GLOBOCAN 2022.
    Int J Cancer. 2025 Jan 10. doi: 10.1002/ijc.35325.
    PubMed     Abstract available


    December 2024
  3. RODRIGUEZ MS, Mahmoud YD, Vanzulli S, Giulianelli S, et al
    FGFR2-RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression.
    Int J Cancer. 2024 Dec 28. doi: 10.1002/ijc.35302.
    PubMed     Abstract available


  4. KOUVARAKI M, Zerdes I, Sifakis EG, Sarafidis M, et al
    Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.
    Int J Cancer. 2024 Dec 27. doi: 10.1002/ijc.35319.
    PubMed     Abstract available


  5. THILL M, Zahn MO, Welt A, Nusch A, et al
    Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.
    Int J Cancer. 2024 Dec 20. doi: 10.1002/ijc.35296.
    PubMed     Abstract available


  6. MOUHANNA P, Stahlberg A, Andersson D, Albu-Kareem A, et al
    Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements.
    Int J Cancer. 2024 Dec 18. doi: 10.1002/ijc.35292.
    PubMed     Abstract available


  7. CHENG TC, Huang BM, Liao YC, Chang HS, et al
    Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35271.
    PubMed     Abstract available


  8. CHEN Y, Salas LA, Marotti JD, Jenkins NP, et al
    Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer.
    Int J Cancer. 2024 Dec 5. doi: 10.1002/ijc.35274.
    PubMed     Abstract available


    November 2024
  9. HOANG T, Lee J, Jung SY, Kim J, et al
    Determining risk-adapted starting age and interval for breast cancer screening based on reproductive and hormonal factors.
    Int J Cancer. 2024 Nov 27. doi: 10.1002/ijc.35265.
    PubMed     Abstract available


  10. LI T, Zhang M, Zhang T, Li S, et al
    Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database.
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35255.
    PubMed     Abstract available


  11. JIANG C, Freedman RA, Punglia RS, Jemal A, et al
    Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States.
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35257.
    PubMed     Abstract available


  12. CAO L, Ou D, Qi WX, Xu C, et al
    A randomized trial of early cardiotoxicity in breast cancer patients receiving postoperative IMRT with or without serial cardiac dose constraints.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35245.
    PubMed     Abstract available


  13. SCHEI-ANDERSEN AJ, Hendricks LAJ, van der Post RS, Mensenkamp AR, et al
    Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single-center study.
    Int J Cancer. 2024;155:1567-1576.
    PubMed     Abstract available


    October 2024
  14. NOGUCHI Y, Ino Y, Kobayashi R, Yoshimura T, et al
    Comment on "Postmarketing adverse events of tamoxifen in male and female patients with breast cancer".
    Int J Cancer. 2024 Oct 29. doi: 10.1002/ijc.35243.
    PubMed    


  15. HOLDER EX, Bigham Z, Nelson KP, Barnard ME, et al
    Mammographic density and breast cancer risk among Black American women.
    Int J Cancer. 2024 Oct 19. doi: 10.1002/ijc.35223.
    PubMed     Abstract available


  16. ARIBAL E, Seker ME, Guldogan N, Yilmaz E, et al
    Value of automated breast ultrasound in screening: Standalone and as a supplemental to digital breast tomosynthesis.
    Int J Cancer. 2024;155:1466-1475.
    PubMed     Abstract available


  17. ZHENG Y, Vdovichenko N, Schurmann P, Ramachandran D, et al
    Comparative sequencing study of mismatch repair and homology-directed repair genes in endometrial cancer and breast cancer patients from Kazakhstan.
    Int J Cancer. 2024 Oct 14. doi: 10.1002/ijc.35215.
    PubMed     Abstract available


  18. HAMAD W, Michell MJ, Myles JP, Gilbert FJ, et al
    Diagnostic performance of tomosynthesis plus synthetic mammography versus full-field digital mammography with or without tomosynthesis in breast cancer screening: A systematic review and meta-analysis.
    Int J Cancer. 2024 Oct 12. doi: 10.1002/ijc.35217.
    PubMed     Abstract available


    September 2024
  19. KE C, Chen M, Lin L, Huang Y, et al
    Postmarketing adverse events of tamoxifen in male and female patients with breast cancer.
    Int J Cancer. 2024 Sep 21. doi: 10.1002/ijc.35193.
    PubMed     Abstract available


  20. PFOB A, Surovtsova I, Kokh DB, Heil J, et al
    Use of chemotherapy and loco-regional therapy in stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study.
    Int J Cancer. 2024 Sep 18. doi: 10.1002/ijc.35189.
    PubMed     Abstract available


  21. BARNES I, Garcia-Closas M, Gathani T, Sweetland S, et al
    A comparative analysis of risk factor associations with interval and screen-detected breast cancers: A large UK prospective study.
    Int J Cancer. 2024;155:979-987.
    PubMed     Abstract available


  22. POISEUIL M, Molinie F, Dabakuyo-Yonli TS, Laville I, et al
    Impact of organized and opportunistic screening on excess mortality and on social inequalities in breast cancer survival.
    Int J Cancer. 2024 Sep 7. doi: 10.1002/ijc.35173.
    PubMed     Abstract available


  23. KOON SUN PAT M, Manraj M, Manraj S
    Breast cancer survival analysis in the Republic of Mauritius by age, stage at diagnosis and molecular subtype: A retrospective cohort study.
    Int J Cancer. 2024 Sep 7. doi: 10.1002/ijc.35172.
    PubMed     Abstract available


    August 2024

  24. RETRACTION: High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells.
    Int J Cancer. 2024 Aug 28. doi: 10.1002/ijc.35151.
    PubMed     Abstract available


  25. LIU B, Song Y, Xu Y, Sun Q, et al
    Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting.
    Int J Cancer. 2024 Aug 23. doi: 10.1002/ijc.35140.
    PubMed     Abstract available


  26. KIM CE, Pereira A, Binder AM, Amarasiriwardena C, et al
    Time-specific impact of trace metals on breast density of adolescent girls in Santiago, Chile.
    Int J Cancer. 2024;155:627-636.
    PubMed     Abstract available


  27. KINDT CK, Alves CL, Ehmsen S, Kragh A, et al
    Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.
    Int J Cancer. 2024 Aug 11. doi: 10.1002/ijc.35126.
    PubMed     Abstract available


    July 2024
  28. LEREVEREND C, Kotaich N, Cartier L, De Boni M, et al
    Enhanced expression of galectin-9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy.
    Int J Cancer. 2024 Jul 30. doi: 10.1002/ijc.35107.
    PubMed     Abstract available



  29. Expression of Concern: Induction of the Death-Promoting Gene bax-alpha Sensitizes Cultured Breast-Cancer Cells to Drug-Induced Apoptosis.
    Int J Cancer. 2024 Jul 26. doi: 10.1002/ijc.35108.
    PubMed    


  30. GABRIELSON M, Hammarstrom M, Bergqvist J, Lang K, et al
    Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
    Int J Cancer. 2024;155:339-351.
    PubMed     Abstract available


  31. JIANG C, Giaquinto AN, Jemal A, Sung H, et al
    Trends in breast cancer incidence by estrogen receptor status in the United States, 2004-2020.
    Int J Cancer. 2024 Jul 10. doi: 10.1002/ijc.35073.
    PubMed     Abstract available


  32. BHIMANI J, O'Connell K, Persaud S, Blinder V, et al
    Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancer.
    Int J Cancer. 2024 Jul 6. doi: 10.1002/ijc.35053.
    PubMed     Abstract available


    June 2024
  33. ANDREOU M, Jakalski M, Duzowska K, Filipowicz N, et al
    Prelude to malignancy: A gene expression signature in normal mammary gland from breast cancer patients suggests pre-tumorous alterations and is associated with adverse outcomes.
    Int J Cancer. 2024 Jun 8. doi: 10.1002/ijc.35050.
    PubMed     Abstract available


    May 2024
  34. DE JONGE C, Schipper RJ, Walstra CJEF, Van Riet YE, et al
    Breast conserving surgery with intraoperative electron beam radiation therapy for low-risk breast cancer: Five-year follow-up of 306 patients.
    Int J Cancer. 2024 May 16. doi: 10.1002/ijc.35033.
    PubMed     Abstract available


  35. HAN X, Liu Y, Zhang S, Li L, et al
    Improving the diagnosis of ductal carcinoma in situ with microinvasion without immunohistochemistry: An innovative method with H&E-stained and multiphoton microscopy images.
    Int J Cancer. 2024;154:1802-1813.
    PubMed     Abstract available


  36. BAO Y, Sui X, Wang X, Qu N, et al
    Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis.
    Int J Cancer. 2024 May 1. doi: 10.1002/ijc.34985.
    PubMed     Abstract available


    April 2024
  37. BRANDT C, Vo JB, Gierach GL, Cheng I, et al
    Second primary cancer risks according to race and ethnicity among U.S. breast cancer survivors.
    Int J Cancer. 2024 Apr 29. doi: 10.1002/ijc.34971.
    PubMed     Abstract available


  38. BUDUKH A, Dora T, Sancheti S, Singh V, et al
    Outcome of early detection approach in control of breast, cervical, and oral cancer: Experience from a rural cancer center in India.
    Int J Cancer. 2024 Apr 20. doi: 10.1002/ijc.34966.
    PubMed     Abstract available


  39. LIN YY, Gao HF, Li H, Hu Q, et al
    Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34945.
    PubMed     Abstract available


  40. PEILA R, Rohan TE
    Circulating levels of biomarkers and risk of ductal carcinoma in situ of the breast in the UK Biobank study.
    Int J Cancer. 2024;154:1191-1203.
    PubMed     Abstract available


  41. WANG Y, Cai W, He P, Cai Q, et al
    Clinical outcomes of coronavirus disease in patients with breast cancer treated with granulocyte colony-stimulating factor following chemotherapy: Triangulation of evidence using population-based cohort and Mendelian randomization analyses.
    Int J Cancer. 2024 Apr 1. doi: 10.1002/ijc.34914.
    PubMed     Abstract available


    March 2024

  42. Correction to "Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database".
    Int J Cancer. 2024 Mar 30. doi: 10.1002/ijc.34925.
    PubMed    


  43. WU H, Wang W, Zhang Y, Chen Y, et al
    Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Int J Cancer. 2024 Mar 27. doi: 10.1002/ijc.34931.
    PubMed     Abstract available


  44. SONGISO M, Nunez O, Cabanes A, Mutale M, et al
    Three-year survival of breast cancer patients attending a one-stop breast care clinic nested within a primary care health facility in sub-Saharan Africa-Zambia.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34920.
    PubMed     Abstract available


  45. DAL MASO L, Toffolutti F, De Paoli A, Giudici F, et al
    Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population-based study in Italy.
    Int J Cancer. 2024 Mar 23. doi: 10.1002/ijc.34923.
    PubMed     Abstract available


  46. WANG T, Chai B, Chen WY, Holmes MD, et al
    Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses' Health Studies.
    Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34917.
    PubMed     Abstract available


  47. SCHMIDT ME, Maurer T, Behrens S, Seibold P, et al
    Cancer-related fatigue: Towards a more targeted approach based on classification by biomarkers and psychological factors.
    Int J Cancer. 2024;154:1011-1018.
    PubMed     Abstract available


  48. KREGTING LM, Vrancken Peeters NJMC, Clarijs ME, Koppert LB, et al
    Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness.
    Int J Cancer. 2024 Mar 13. doi: 10.1002/ijc.34899.
    PubMed     Abstract available


  49. LUFTNER D, Schuetz F, Schneeweiss A, Hartkopf A, et al
    Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34912.
    PubMed     Abstract available


  50. LIU X, Xie X, Sui C, Liu X, et al
    Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900.
    PubMed     Abstract available


    February 2024
  51. TANG T, Yu H, Xu S, Zhong Y, et al
    Causal effects of endometriosis on cancer risk: A Mendelian randomization study.
    Int J Cancer. 2024 Feb 7. doi: 10.1002/ijc.34876.
    PubMed     Abstract available


  52. SVANOE AA, Humlevik ROC, Knutsvik G, Saele AKM, et al
    Age-related phenotypes in breast cancer: A population-based study.
    Int J Cancer. 2024 Feb 6. doi: 10.1002/ijc.34863.
    PubMed     Abstract available


    January 2024
  53. RYBINSKA I, Mangano N, Romero-Cordoba SL, Regondi V, et al
    SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness.
    Int J Cancer. 2024 Jan 30. doi: 10.1002/ijc.34859.
    PubMed     Abstract available


  54. SHARMA MP, Shukla S, Misra G
    Recent advances in breast cancer cell line research.
    Int J Cancer. 2024 Jan 17. doi: 10.1002/ijc.34849.
    PubMed     Abstract available


  55. JENSEN HAR, Horsbol TA, Thygesen LC, Davidsen M, et al
    Variations in the agreement of self-reported cancer: A Danish nationwide study.
    Int J Cancer. 2024;154:217-225.
    PubMed     Abstract available


  56. CHEN H, Yang G, Ma J
    Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database.
    Int J Cancer. 2024 Jan 12. doi: 10.1002/ijc.34848.
    PubMed     Abstract available


  57. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    PubMed     Abstract available


    November 2023

  58. Retraction: Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct down-regulation of MCAM in triple-negative breast cancer cells. De Zeng, Yuan-Ke Liang, Ying-Sheng Xiao, Xiao-Long Wei, Hao-Yu Lin, Yang Wu, Jing-Wen Bai, Min Ch
    Int J Cancer. 2023 Nov 20. doi: 10.1002/ijc.34792.
    PubMed     Abstract available


  59. JANSEN L, Schwettmann L, Behr C, Eberle A, et al
    Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to 2018: An ecological registry-based study.
    Int J Cancer. 2023;153:1784-1796.
    PubMed     Abstract available


  60. RANGANATHAN S, Dee EC, Debnath N, Patel TA, et al
    Access and barriers to genomic classifiers for breast cancer and prostate cancer in India.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34784.
    PubMed     Abstract available


  61. YANG F, Sun D, Ding C, Xia C, et al
    Global patterns of cancer transitions: A modelling study.
    Int J Cancer. 2023;153:1612-1622.
    PubMed     Abstract available


    October 2023
  62. ROSAS JC, Aguado-Barrera ME, Azria D, Briers E, et al
    Reply to: Comments on "(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34772.
    PubMed    


  63. CHEN H, Feng L
    Comment on "(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34770.
    PubMed    


  64. YU Z, Dong X, Song M, Xu A, et al
    Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34769.
    PubMed     Abstract available


  65. RUGO HS, Liu X, Li B, McRoy L, et al
    Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
    Int J Cancer. 2023 Oct 13. doi: 10.1002/ijc.34748.
    PubMed     Abstract available


  66. ZEVERIJN LJ, Looze EJ, Thavaneswaran S, van Berge Henegouwen JM, et al
    Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
    Int J Cancer. 2023;153:1413-1422.
    PubMed     Abstract available


    September 2023
  67. HYUNG J, Lee SB, Kim J, Kim HJ, et al
    21-gene expression assay and clinical outcomes of premenopausal patients with hormone receptor-positive breast cancer.
    Int J Cancer. 2023 Sep 17. doi: 10.1002/ijc.34728.
    PubMed     Abstract available


  68. DHOKOTERA TG, Muchengeti M, Davidovic M, Rohner E, et al
    Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study.
    Int J Cancer. 2023 Sep 8. doi: 10.1002/ijc.34712.
    PubMed     Abstract available


  69. LIU J, He M, Ou K, Wang X, et al
    Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.
    Int J Cancer. 2023 Sep 7. doi: 10.1002/ijc.34717.
    PubMed     Abstract available


    August 2023
  70. LIGORIO F, Lobefaro R, Fuca G, Provenzano L, et al
    Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
    Int J Cancer. 2023 Aug 24. doi: 10.1002/ijc.34701.
    PubMed     Abstract available


  71. MAKHETHA M, Chabilal N, Aldous C
    Recent trends in hereditary breast cancer incidence by race and age in KwaZulu-Natal, South Africa: An 11-year single-centre retrospective study (2011-2021).
    Int J Cancer. 2023 Aug 14. doi: 10.1002/ijc.34687.
    PubMed     Abstract available


  72. ALLALI S, Carton M, Everhard S, Rivera S, et al
    CANTO skin: Evaluation of skin toxicity risk factors in patients treated for breast cancer.
    Int J Cancer. 2023 Aug 12. doi: 10.1002/ijc.34664.
    PubMed     Abstract available



  73. Correction to Breast cancer rate after oophorectomy: A Prospective Danish Cohort Study.
    Int J Cancer. 2023 Aug 8. doi: 10.1002/ijc.34653.
    PubMed    


  74. LI Y, Tong Z, Wu X, Ouyang Q, et al
    Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study.
    Int J Cancer. 2023 Aug 6. doi: 10.1002/ijc.34676.
    PubMed     Abstract available


    July 2023
  75. ROCHE ME, Ko YH, Domingo-Vidal M, Lin Z, et al
    TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer.
    Int J Cancer. 2023 Jul 27. doi: 10.1002/ijc.34660.
    PubMed     Abstract available


  76. ROSAS JC, Aguado-Barrera ME, Azria D, Briers E, et al
    (Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer.
    Int J Cancer. 2023 Jul 5. doi: 10.1002/ijc.34640.
    PubMed     Abstract available


    June 2023
  77. BEDDOK A, Mouren V, Cottu P, Laki F, et al
    Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.
    Int J Cancer. 2023 Jun 28. doi: 10.1002/ijc.34562.
    PubMed     Abstract available


  78. SCHMIDT ME, Chong M, Klassen O, Wiskemann J, et al
    Longitudinal associations of bioelectrical phase angle and fatigue in breast cancer patients.
    Int J Cancer. 2023 Jun 20. doi: 10.1002/ijc.34630.
    PubMed     Abstract available


  79. NAIMO GD, Forestiero M, Paoli A, Malivindi R, et al
    ERalpha/LKB1 complex upregulates E-cadherin expression and stimulates breast cancer growth and progression upon adiponectin exposure.
    Int J Cancer. 2023 Jun 16. doi: 10.1002/ijc.34626.
    PubMed     Abstract available


  80. PAGANO C, di Zazzo E, Avilia G, Savarese B, et al
    Advances in "adiponcosis": Insights in the inner mechanisms at the base of adipose and tumour tissues interplay.
    Int J Cancer. 2023;152:2464-2473.
    PubMed     Abstract available


  81. JIANG M, Liu J, Li Q, Xu B, et al
    The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status.
    Int J Cancer. 2023 Jun 14. doi: 10.1002/ijc.34570.
    PubMed     Abstract available


  82. ROMANENS L, Chaskar P, Marcone R, Ryser S, et al
    Clonal expansion of intra-epithelial T cells in breast cancer revealed by spatial transcriptomics.
    Int J Cancer. 2023 Jun 12. doi: 10.1002/ijc.34620.
    PubMed     Abstract available


  83. RAJKOVIC SM, Charalambous MP, Charalambous CP, Simic LD, et al
    Higher rate of progesterone receptor positivity in skeletal metastases of breast cancer with a pathological fracture vs those without fracture.
    Int J Cancer. 2023 Jun 2. doi: 10.1002/ijc.34605.
    PubMed     Abstract available


  84. WITHROW DR, Nicholson BD, Morris EJA, Wong ML, et al
    Age-related differences in cancer relative survival in the United States: A SEER-18 analysis.
    Int J Cancer. 2023;152:2283-2291.
    PubMed     Abstract available


  85. GABRIELSON M, Hammarstrom M, Backlund M, Bergqvist J, et al
    Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women.
    Int J Cancer. 2023;152:2362-2372.
    PubMed     Abstract available


    May 2023
  86. KUANG X, Luo Z, Sun Z, Hu J, et al
    Distinct invasive patterns in situ between estrogen receptor-positive and triple-negative breast cancer through the intraductal tracking of carbon nanoparticles.
    Int J Cancer. 2023 May 31. doi: 10.1002/ijc.34611.
    PubMed     Abstract available


  87. SONG H, Jung YS, Tran TXM, Moon CM, et al
    Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study.
    Int J Cancer. 2023 May 29. doi: 10.1002/ijc.34573.
    PubMed     Abstract available


  88. GRIGUOLO G, Aldegheri V, Bottosso M, Pittaro A, et al
    Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients.
    Int J Cancer. 2023 May 27. doi: 10.1002/ijc.34571.
    PubMed     Abstract available


  89. SYLEOUNI ME, Karavasiloglou N, Manduchi L, Wanner M, et al
    Predicting second breast cancer among women with primary breast cancer using machine learning algorithms, a population-based observational study.
    Int J Cancer. 2023 May 27. doi: 10.1002/ijc.34568.
    PubMed     Abstract available


  90. KRISTIANSEN MF, Mikkelsen RM, Kristiansdottir T, Andorsdottir G, et al
    Cancer survival in the Faroe Islands over the last 50 years compared to the other Nordic countries.
    Int J Cancer. 2023;152:2090-2098.
    PubMed     Abstract available


    April 2023
  91. KANNAN S, Cheng VWT
    Nanoparticle drug delivery to target breast cancer brain metastasis: Current and future trends.
    Int J Cancer. 2023 Apr 25. doi: 10.1002/ijc.34542.
    PubMed     Abstract available


  92. RANTALA JNJ, Heikkinen SMM, Hirvonen EM, Tanskanen T, et al
    Familial aggregation of early-onset cancers in early-onset breast cancer families.
    Int J Cancer. 2023 Apr 19. doi: 10.1002/ijc.34538.
    PubMed     Abstract available


  93. JERARD C, Madhusudanan P, Swamy A, Ravikumar K, et al
    Secretome mediated interactions between sensory neurons and breast cancer cells.
    Int J Cancer. 2023 Apr 17. doi: 10.1002/ijc.34529.
    PubMed     Abstract available


  94. KREGTING LM, van Ravesteyn NT, Chootipongchaivat S, Heijnsdijk EAM, et al
    Cumulative risks of false positive recall and screen-detected breast cancer after multiple screening examinations.
    Int J Cancer. 2023 Apr 10. doi: 10.1002/ijc.34530.
    PubMed     Abstract available


  95. VAN STEENHOVEN JEC, van Maaren MC, Verreck EEF, Schipper RJ, et al
    Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: Innovative hospitals are early adopters of a de-escalating approach.
    Int J Cancer. 2023;152:1378-1387.
    PubMed     Abstract available


  96. WAGENER R, Walter C, Auer F, Alzoubi D, et al
    The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients.
    Int J Cancer. 2023;152:1388-1398.
    PubMed     Abstract available


    March 2023
  97. SENKUS E, Delaloge S, Domchek SM, Conte P, et al
    Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial.
    Int J Cancer. 2023 Mar 27. doi: 10.1002/ijc.34525.
    PubMed     Abstract available


  98. QIN Z, Li J, Tam B, Sinha S, et al
    Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population.
    Int J Cancer. 2023;152:1159-1173.
    PubMed     Abstract available


  99. CARDOSO R, Hoffmeister M, Brenner H
    Breast cancer screening programmes and self-reported mammography use in European countries.
    Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34494.
    PubMed     Abstract available


    February 2023
  100. CHANG VC, Rhee J, Berndt SI, Moore SC, et al
    Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34487.
    PubMed     Abstract available


  101. LIU S, van Dinther M, Hagenaars SC, Gu Y, et al
    Differential Optineurin expression controls TGFbeta signaling and is a key determinant for metastasis of triple negative breast cancer.
    Int J Cancer. 2023 Feb 23. doi: 10.1002/ijc.34483.
    PubMed     Abstract available


  102. XIA C, Yu XQ, Chen W
    Measuring population-level cure patterns for cancer patients in the United States.
    Int J Cancer. 2023;152:738-748.
    PubMed     Abstract available


  103. JIA G, Yang Y, Ping J, Xu S, et al
    Identification of target proteins for breast cancer genetic risk loci and blood risk biomarkers in a large study by integrating genomic and proteomic data.
    Int J Cancer. 2023 Feb 13. doi: 10.1002/ijc.34472.
    PubMed     Abstract available


  104. GETU MA, Chen C, Addissie A, Seife E, et al
    The effect of cognitive behavioural therapy integrated with activity pacing on cancer-related fatigue, depression and quality of life among patients with breast cancer undergoing chemotherapy in Ethiopia: a randomised clinical trial.
    Int J Cancer. 2023 Feb 6. doi: 10.1002/ijc.34452.
    PubMed     Abstract available


    January 2023
  105. GONZALEZ-CALLEJO P, Gener P, Diaz-Riascos ZV, Conti S, et al
    Extracellular vesicles secreted by triple negative breast cancer stem cells trigger pre-metastatic niche remodeling and metastatic growth in the lungs.
    Int J Cancer. 2023 Jan 27. doi: 10.1002/ijc.34447.
    PubMed     Abstract available


  106. XU B, Ma F, Wang T, Wang S, et al
    A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments.
    Int J Cancer. 2023 Jan 9. doi: 10.1002/ijc.34424.
    PubMed     Abstract available


  107. KAR A, Medatwal N, Rajput K, Mandal S, et al
    Unique Sphingolipid Signature Identifies Luminal and Triple-Negative Breast Cancer Subtypes.
    Int J Cancer. 2023 Jan 5. doi: 10.1002/ijc.34423.
    PubMed     Abstract available


    December 2022
  108. BOUCHERON P, Anele A, Offiah AU, Zietsman A, et al
    Reproductive history and breast cancer survival: findings from the African Breast Cancer - Disparities in Outcomes cohort and implications of Africa's fertility transition on breast cancer prognosis.
    Int J Cancer. 2022 Dec 22. doi: 10.1002/ijc.34411.
    PubMed     Abstract available


    November 2022
  109. HEY J, Halperin C, Hartmann M, Mayer S, et al
    DNA methylation landscape of tumor-associated macrophages reveals pathways, transcription factors, and prognostic value relevant to triple-negative breast cancer patients.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34364.
    PubMed     Abstract available


  110. LIN M, Jin Y, Lv H, Hu X, et al
    Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34365.
    PubMed     Abstract available


  111. ARMAROLI P, Frigerio A, Correale L, Ponti A, et al
    A randomised controlled trial of digital breast tomosynthesis vs digital mammography as primary screening tests: Screening results over subsequent episodes of the Proteus Donna study.
    Int J Cancer. 2022;151:1778-1790.
    PubMed     Abstract available


  112. ALCARAZ LB, Mallavialle A, Mollevi C, Boissiere-Michot F, et al
    SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34345.
    PubMed     Abstract available


  113. CAIRAT M, Pottegard A, Olesen M, Dossus L, et al
    Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34343.
    PubMed     Abstract available


    October 2022
  114. MANOOCHEHRI M, Borhani N, Gerhauser C, Assenov Y, et al
    DNA methylation biomarkers for non-invasive detection of triple negative breast cancer using liquid biopsy.
    Int J Cancer. 2022 Oct 28. doi: 10.1002/ijc.34337.
    PubMed     Abstract available


  115. CARIOLOU M, Abar L, Aune D, Balducci K, et al
    Postdiagnosis recreational physical activity and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34324.
    PubMed     Abstract available


  116. BECERRA-TOMAS N, Balducci K, Abar L, Aune D, et al
    Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34321.
    PubMed     Abstract available


  117. TSILIDIS KK, Cariolou M, Becerra-Tomas N, Balducci K, et al
    Postdiagnosis body fatness, recreational physical activity, dietary factors and breast cancer prognosis: Global Cancer Update Programme (CUP Global) summary of evidence grading.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34320.
    PubMed     Abstract available


  118. CHAN DSM, Vieira R, Abar L, Aune D, et al
    Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34322.
    PubMed     Abstract available


  119. LYNGE E, Vjeborg I, Lillholm M, Nielsen M, et al
    Breast Density and Risk of Breast Cancer.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34316.
    PubMed     Abstract available


  120. BAHAR-SHANY K, Barnabas GD, Deutsch L, Deutsch N, et al
    Proteomic Signature for Detection of High Grade Ovarian Cancer in germline BRCA mutation carriers.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34318.
    PubMed     Abstract available


    September 2022
  121. KANKURI-TAMMILEHTO M, Tervasmaki A, Kraatari-Tiri M, Rahikkala E, et al
    ATM c.7570G>C is a high-risk allele for breast cancer.
    Int J Cancer. 2022 Sep 26. doi: 10.1002/ijc.34305.
    PubMed     Abstract available


  122. MAILLIEZ A, D'Hondt V, Lusque A, Caron O, et al
    Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
    Int J Cancer. 2022 Sep 26. doi: 10.1002/ijc.34304.
    PubMed     Abstract available


  123. WU J, Tan X
    The role of MTNR1B polymorphism on circadian rhythm-related cancer: A UK Biobank cohort study.
    Int J Cancer. 2022;151:888-896.
    PubMed     Abstract available


    August 2022
  124. LOK SW, De Boer R, Baron-Hay S, Button P, et al
    Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA).
    Int J Cancer. 2022 Aug 16. doi: 10.1002/ijc.34245.
    PubMed     Abstract available


  125. KREGTING LM, Sankatsing VDV, Heijnsdijk EAM, de Koning HJ, et al
    Reply to: Comments on "Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modeled strategies".
    Int J Cancer. 2022;151:651-652.
    PubMed    


  126. BRAILLON A
    Comments on "Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modeled strategies".
    Int J Cancer. 2022;151:649-650.
    PubMed    


  127. PEILA R, Lane DS, Shadyab AH, Saquib N, et al
    Healthy lifestyle index and the risk of ductal carcinoma in situ of the breast in the Women's Health Initiative.
    Int J Cancer. 2022;151:526-538.
    PubMed     Abstract available


    July 2022
  128. MATTA M, Deubler E, Chajes V, Vozar B, et al
    Circulating plasma phospholipid fatty acid levels and breast cancer risk in the Cancer Prevention Study-II Nutrition Cohort.
    Int J Cancer. 2022 Jul 18. doi: 10.1002/ijc.34216.
    PubMed     Abstract available


  129. KREGTING LM, Sankatsing VDV, Heijnsdijk EAM, de Koning HJ, et al
    Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies.
    Int J Cancer. 2022;151:287-296.
    PubMed     Abstract available


  130. BASSETT JK, MacInnis RJ, Yang Y, Hodge AM, et al
    Alcohol intake trajectories during the life course and risk of alcohol-related cancer: A prospective cohort study.
    Int J Cancer. 2022;151:56-66.
    PubMed     Abstract available


    June 2022
  131. KARAVASILOGLOU N, Pestoni G, Kuhn T, Rohrmann S, et al
    Adherence to cancer prevention recommendations and risk of breast cancer in situ in the United Kingdom Biobank.
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34183.
    PubMed     Abstract available


  132. DESCHASAUX-TANGUY M, Barrubes Pinol L, Sellem L, Debras C, et al
    Dairy product consumption and risk of cancer: A short report from the NutriNet-Sante prospective cohort study.
    Int J Cancer. 2022;150:1978-1986.
    PubMed     Abstract available


  133. RATOSA I, Dobnikar N, Bottosso M, Dieci MV, et al
    Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: real-world data from a multicentric European cohort.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34135.
    PubMed     Abstract available


  134. WU Z, Byrd DA, Wan Y, Ansong D, et al
    The oral microbiome and breast cancer and non-malignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34145.
    PubMed     Abstract available


  135. HENNINGSEN MB, McWhan K, Dam VS, Mele M, et al
    Amplified Ca(2+) dynamics and accelerated cell proliferation in breast cancer tissue during purinergic stimulation.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34147.
    PubMed     Abstract available


    April 2022
  136. ALLALI S, Carton M, Sarrade T, Querel O, et al
    CANTO-RT: Skin toxicities evaluation of a multicenter large prospective cohort of irradiated patients for early-stage breast cancer.
    Int J Cancer. 2022 Apr 30. doi: 10.1002/ijc.34057.
    PubMed     Abstract available


  137. TRAN TXM, Kim S, Song H, Park B, et al
    Mammographic Breast Density, Body Mass Index, and Risk of Breast Cancer in Korean Women Aged 75 Years and Older.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34038.
    PubMed     Abstract available


  138. BOUWER NI, Steenbruggen TG, Rier HN, Kitzen JJ, et al
    The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
    Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34024.
    PubMed     Abstract available


  139. CHEN F, Wen W, Long J, Shu X, et al
    Mendelian randomization analyses of 23 known and suspected risk factors and biomarkers for breast cancer overall and by molecular subtypes.
    Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34026.
    PubMed     Abstract available


  140. XIU M, Zhang P, Wang X, Fan Y, et al
    Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant versus standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: a prospective cohort study with propensity-matched analysis.
    Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34022.
    PubMed     Abstract available


  141. RASHID MU, Muhammad N, Naeemi H, Shehzad U, et al
    Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34016.
    PubMed     Abstract available


    March 2022
  142. XIE Y, Zhang Y, Xie K, Zhong X, et al
    Impact of time to initiation of postoperative radiotherapy after neoadjuvant chemotherapy on the prognosis of breast cancer: a retrospective cohort study in China.
    Int J Cancer. 2022 Mar 25. doi: 10.1002/ijc.34003.
    PubMed     Abstract available


  143. WATT GP, Knight JA, Nguyen TL, Reiner AS, et al
    Association of contralateral breast cancer risk with mammographic density defined at higher-than-conventional intensity thresholds.
    Int J Cancer. 2022 Mar 22. doi: 10.1002/ijc.34001.
    PubMed     Abstract available


    February 2022
  144. AYENI OA, O'Neil DS, Pumpalova YS, Chen WC, et al
    Impact of HIV infection on Survival among Women with Stage I-III Breast Cancer: Results from the South African Breast Cancer and HIV Outcomes Study.
    Int J Cancer. 2022 Feb 26. doi: 10.1002/ijc.33981.
    PubMed     Abstract available


  145. HAFSTAETH V, Sokilde R, Hakkinen J, Larsson M, et al
    Regulatory networks and 5' partner usage of miRNA host gene fusions in breast cancer.
    Int J Cancer. 2022 Feb 19. doi: 10.1002/ijc.33972.
    PubMed     Abstract available


  146. JOHANSSON A, Yiu-Lin Yu N, Iftimi A, Tobin NP, et al
    Clinical and Molecular Characteristics of ER-Positive Ultralow Risk Breast Cancer Tumors Identified by the 70-Gene Signature.
    Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33969.
    PubMed     Abstract available


  147. HA MJ, Raghavendra AS, Kettner NM, Qiao W, et al
    Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting-a large institutional study.
    Int J Cancer. 2022 Feb 8. doi: 10.1002/ijc.33959.
    PubMed     Abstract available


  148. FLUGELMAN AA, Burton A, Keinan-Boker L, Stein N, et al
    Correlation between cumulative mammographic density and age - specific incidence of breast cancer: a bi-ethnic study in israel.
    Int J Cancer. 2022 Feb 6. doi: 10.1002/ijc.33957.
    PubMed     Abstract available


    January 2022
  149. SWERDLOW AJ, Bruce C, Cooke R, Coulson P, et al
    Risk of breast cancer in men in relation to weight change: a national case-control study in England and Wales.
    Int J Cancer. 2022 Jan 20. doi: 10.1002/ijc.33938.
    PubMed     Abstract available


  150. MAILLIEZ A, Pigny P, Bogart E, Keller L, et al
    Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients.
    Int J Cancer. 2022 Jan 17. doi: 10.1002/ijc.33933.
    PubMed     Abstract available


  151. GOTTSCHAU M, Bens A, Friis S, Cronin-Fenton D, et al
    Use of beta-blockers and risk of contralateral breast cancer.
    Int J Cancer. 2022 Jan 5. doi: 10.1002/ijc.33923.
    PubMed     Abstract available


    December 2021
  152. ZHOU W, Jiang Y, Xu Y, Wang Y, et al
    Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: a propensity-score matched cohort study.
    Int J Cancer. 2021 Dec 26. doi: 10.1002/ijc.33919.
    PubMed     Abstract available


  153. ABASCAL MF, Elia A, Alvarez M, Pataccini G, et al
    Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.
    Int J Cancer. 2021 Dec 22. doi: 10.1002/ijc.33913.
    PubMed     Abstract available


  154. WEGE AK, Rom-Jurek EM, Jank P, Denkert C, et al
    mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease.
    Int J Cancer. 2021 Dec 20. doi: 10.1002/ijc.33911.
    PubMed     Abstract available


  155. PARK B
    Changes in weight and waist circumference during menopausal transition and postmenopausal breast cancer risk.
    Int J Cancer. 2021 Dec 18. doi: 10.1002/ijc.33906.
    PubMed     Abstract available


    November 2021
  156. LOAP P, Loirat D, Berger F, Cao K, et al
    Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial.
    Int J Cancer. 2021;149:1828-1832.
    PubMed     Abstract available


  157. KIM DS, Ahn HS, Kim HJ
    Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database.
    Int J Cancer. 2021 Nov 9. doi: 10.1002/ijc.33869.
    PubMed     Abstract available


    October 2021
  158. WANG C, Gu K, Wang F, Cai H, et al
    Nut consumption in association with overall mortality and recurrence/disease-specific mortality among long-term breast cancer survivors.
    Int J Cancer. 2021 Oct 19. doi: 10.1002/ijc.33824.
    PubMed     Abstract available


  159. YE C, Zhou W, Wang F, Yin G, et al
    Prognostic Value of GILT Expression in Female Patients Diagnosed with Breast Cancer.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33843.
    PubMed     Abstract available


    September 2021
  160. ZHANG L, Wu ZY, Li J, Lin Y, et al
    Neoadjuvant Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel in Triple-Negative, Early-Stage Breast Cancer (NeoCART): Results from a Multicenter, Randomized Controlled, Open-Label Phase II Trial.
    Int J Cancer. 2021 Sep 30. doi: 10.1002/ijc.33830.
    PubMed     Abstract available


  161. POISEUIL M, Tron L, Woronoff AS, Tretarre B, et al
    How do age and social environment affect the dynamics of death hazard and survival in patients with breast or gynecological cancer in France?
    Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33803.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.